Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.90
ICLR's Cash-to-Debt is ranked lower than
66% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ICLR: 0.90 )
Ranked among companies with meaningful Cash-to-Debt only.
ICLR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.55  Med: 11.78 Max: No Debt
Current: 0.9
Equity-to-Asset 0.54
ICLR's Equity-to-Asset is ranked lower than
65% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ICLR: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
ICLR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.64 Max: 0.77
Current: 0.54
0.44
0.77
Debt-to-Equity 0.34
ICLR's Debt-to-Equity is ranked lower than
55% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. ICLR: 0.34 )
Ranked among companies with meaningful Debt-to-Equity only.
ICLR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.09 Max: 0.46
Current: 0.34
0
0.46
Interest Coverage 25.13
ICLR's Interest Coverage is ranked lower than
58% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. ICLR: 25.13 )
Ranked among companies with meaningful Interest Coverage only.
ICLR' s Interest Coverage Range Over the Past 10 Years
Min: 17.93  Med: 42.14 Max: 257.77
Current: 25.13
17.93
257.77
Piotroski F-Score: 7
Altman Z-Score: 6.38
Beneish M-Score: -2.66
WACC vs ROIC
4.01%
27.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 18.94
ICLR's Operating Margin % is ranked higher than
90% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. ICLR: 18.94 )
Ranked among companies with meaningful Operating Margin % only.
ICLR' s Operating Margin % Range Over the Past 10 Years
Min: 3.11  Med: 11.24 Max: 18.94
Current: 18.94
3.11
18.94
Net Margin % 15.97
ICLR's Net Margin % is ranked higher than
91% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. ICLR: 15.97 )
Ranked among companies with meaningful Net Margin % only.
ICLR' s Net Margin % Range Over the Past 10 Years
Min: 2.42  Med: 9.35 Max: 15.97
Current: 15.97
2.42
15.97
ROE % 28.45
ICLR's ROE % is ranked higher than
92% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. ICLR: 28.45 )
Ranked among companies with meaningful ROE % only.
ICLR' s ROE % Range Over the Past 10 Years
Min: 3.39  Med: 17.27 Max: 30.7
Current: 28.45
3.39
30.7
ROA % 14.85
ICLR's ROA % is ranked higher than
91% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. ICLR: 14.85 )
Ranked among companies with meaningful ROA % only.
ICLR' s ROA % Range Over the Past 10 Years
Min: 2.31  Med: 9.79 Max: 14.85
Current: 14.85
2.31
14.85
ROC (Joel Greenblatt) % 92.36
ICLR's ROC (Joel Greenblatt) % is ranked higher than
91% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ICLR: 92.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ICLR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.45  Med: 41.07 Max: 121.76
Current: 92.36
12.45
121.76
3-Year Revenue Growth Rate 11.20
ICLR's 3-Year Revenue Growth Rate is ranked higher than
66% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. ICLR: 11.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ICLR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.6  Med: 11.75 Max: 54.3
Current: 11.2
-14.6
54.3
3-Year EBITDA Growth Rate 34.60
ICLR's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ICLR: 34.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ICLR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.1 Max: 52.9
Current: 34.6
0
52.9
3-Year EPS without NRI Growth Rate 41.30
ICLR's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. ICLR: 41.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ICLR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34.2  Med: 8.15 Max: 94.7
Current: 41.3
-34.2
94.7
GuruFocus has detected 3 Warning Signs with Icon PLC $ICLR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ICLR's 30-Y Financials

Financials (Next Earnings Date: 2017-10-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ICLR Guru Trades in Q3 2016

Scott Black 29,492 sh (New)
Jeremy Grantham 44,200 sh (+68.06%)
Jim Simons 212,200 sh (+38.33%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 928,453 sh (-0.31%)
Steven Cohen 161,200 sh (-3.42%)
» More
Q4 2016

ICLR Guru Trades in Q4 2016

Jim Simons 271,100 sh (+27.76%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 879,550 sh (-5.27%)
Steven Cohen 138,500 sh (-14.08%)
Scott Black 20,584 sh (-30.20%)
Jeremy Grantham 3,129 sh (-92.92%)
» More
Q1 2017

ICLR Guru Trades in Q1 2017

Jim Simons 955,860 sh (+252.59%)
Steven Cohen 369,500 sh (+166.79%)
Chuck Royce 143,700 sh (unchged)
Scott Black Sold Out
Jeremy Grantham Sold Out
Ron Baron 829,200 sh (-5.72%)
» More
Q2 2017

ICLR Guru Trades in Q2 2017

Caxton Associates 5,300 sh (New)
Paul Tudor Jones 3,718 sh (New)
Joel Greenblatt 4,004 sh (New)
Jim Simons 1,153,160 sh (+20.64%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 804,200 sh (-3.01%)
Steven Cohen 2,000 sh (-99.46%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Reduce -3.01%0.01%$76.83 - $98.43 $ 110.6826%804,200
Joel Greenblatt 2017-06-30 New Buy0.01%$76.83 - $98.43 $ 110.6826%4,004
Ron Baron 2017-03-31 Reduce -5.72%0.02%$74.71 - $87.78 $ 110.6835%829,200
Ron Baron 2016-12-31 Reduce -5.27%0.02%$74.34 - $85.04 $ 110.6843%879,550
Ron Baron 2016-09-30 Reduce -0.31%$69.7 - $78.69 $ 110.6847%928,453
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711 
Compare:NAS:TRIB » details
Traded in other countries:0NBW.UK,
Headquarter Location:Ireland
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Icon is a global contract research organization that provides drug development and clinical testing services to pharmaceutical, biotechnology, and medical device companies. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities.

Top Ranked Articles about Icon PLC

Scott Black’s Top 4 New Holdings of 3rd Quarter Guru’s largest purchase is research and development company
Scott Black (Trades, Portfolio), president and founder of Delphi Management, acquired nine new holdings in the third quarter. His top four new positions are Icon PLC (NASDAQ:ICLR), Lionbridge Technologies (NASDAQ:LIOX), Omega Healthcare Investors (NYSE:OHI) and National General Holdings Corp. (NASDAQ:NGHC). Read more...
9 Companies Grantham Continues to Boost Stocks the investor bought in the 2nd and 3rd quarters
Jeremy Grantham (Trades, Portfolio) is the chairman of Grantham Mayo Van Otterloo, a Boston-based asset management firm. In both the second and third quarters the guru bought shares in the following stocks: Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.32
ICLR's PE Ratio is ranked higher than
79% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. ICLR: 22.32 )
Ranked among companies with meaningful PE Ratio only.
ICLR' s PE Ratio Range Over the Past 10 Years
Min: 9.92  Med: 18.42 Max: 80.63
Current: 22.32
9.92
80.63
Forward PE Ratio 19.05
ICLR's Forward PE Ratio is ranked higher than
89% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. ICLR: 19.05 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.32
ICLR's PE Ratio without NRI is ranked higher than
79% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. ICLR: 22.32 )
Ranked among companies with meaningful PE Ratio without NRI only.
ICLR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.92  Med: 18.39 Max: 80.63
Current: 22.32
9.92
80.63
Price-to-Owner-Earnings 21.45
ICLR's Price-to-Owner-Earnings is ranked higher than
72% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. ICLR: 21.45 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ICLR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.23  Med: 24.47 Max: 437.5
Current: 21.45
6.23
437.5
PB Ratio 5.75
ICLR's PB Ratio is ranked lower than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ICLR: 5.75 )
Ranked among companies with meaningful PB Ratio only.
ICLR' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.58 Max: 6.04
Current: 5.75
1.34
6.04
PS Ratio 3.56
ICLR's PS Ratio is ranked higher than
58% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ICLR: 3.56 )
Ranked among companies with meaningful PS Ratio only.
ICLR' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.63 Max: 3.73
Current: 3.56
0.87
3.73
Price-to-Free-Cash-Flow 19.65
ICLR's Price-to-Free-Cash-Flow is ranked higher than
72% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. ICLR: 19.65 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ICLR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.85  Med: 20.43 Max: 533.56
Current: 19.65
5.85
533.56
Price-to-Operating-Cash-Flow 17.52
ICLR's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. ICLR: 17.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ICLR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.07  Med: 16.23 Max: 86.1
Current: 17.52
5.07
86.1
EV-to-EBIT 18.25
ICLR's EV-to-EBIT is ranked higher than
76% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 18.25 )
Ranked among companies with meaningful EV-to-EBIT only.
ICLR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 15.35 Max: 48
Current: 18.25
8.1
48
EV-to-EBITDA 15.48
ICLR's EV-to-EBITDA is ranked higher than
71% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. ICLR: 15.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICLR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 12.2 Max: 23.6
Current: 15.48
6.3
23.6
EV-to-Revenue 3.48
ICLR's EV-to-Revenue is ranked higher than
62% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ICLR: 3.48 )
Ranked among companies with meaningful EV-to-Revenue only.
ICLR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 1.55 Max: 3.7
Current: 3.48
0.8
3.7
PEG Ratio 0.52
ICLR's PEG Ratio is ranked higher than
98% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. ICLR: 0.52 )
Ranked among companies with meaningful PEG Ratio only.
ICLR' s PEG Ratio Range Over the Past 10 Years
Min: 0.34  Med: 1.4 Max: 8.54
Current: 0.52
0.34
8.54
Shiller PE Ratio 46.29
ICLR's Shiller PE Ratio is ranked higher than
61% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. ICLR: 46.29 )
Ranked among companies with meaningful Shiller PE Ratio only.
ICLR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.01  Med: 24.55 Max: 49.29
Current: 46.29
10.01
49.29
Current Ratio 2.11
ICLR's Current Ratio is ranked lower than
63% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ICLR: 2.11 )
Ranked among companies with meaningful Current Ratio only.
ICLR' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 2.11
1.12
3.61
Quick Ratio 2.11
ICLR's Quick Ratio is ranked lower than
58% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ICLR: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
ICLR' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 2.11
1.12
3.61
Days Sales Outstanding 76.45
ICLR's Days Sales Outstanding is ranked lower than
61% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. ICLR: 76.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICLR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.88  Med: 89.44 Max: 94.82
Current: 76.45
66.88
94.82
Days Payable 98.78
ICLR's Days Payable is ranked higher than
75% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. ICLR: 98.78 )
Ranked among companies with meaningful Days Payable only.
ICLR' s Days Payable Range Over the Past 10 Years
Min: 1.98  Med: 11.29 Max: 130.79
Current: 98.78
1.98
130.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.00
ICLR's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ICLR: 4.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICLR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.5  Med: -1.45 Max: 16.4
Current: 4
-61.5
16.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 39.67
ICLR's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. ICLR: 39.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICLR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.88  Med: 7.12 Max: 60.14
Current: 39.67
0.88
60.14
Price-to-Tangible-Book 16.82
ICLR's Price-to-Tangible-Book is ranked lower than
90% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. ICLR: 16.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICLR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.64  Med: 3.62 Max: 39.34
Current: 16.82
0.64
39.34
Price-to-Intrinsic-Value-Projected-FCF 1.80
ICLR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ICLR: 1.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ICLR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.71 Max: 6.7
Current: 1.8
0.51
6.7
Price-to-Median-PS-Value 2.20
ICLR's Price-to-Median-PS-Value is ranked lower than
89% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. ICLR: 2.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICLR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.9 Max: 2.22
Current: 2.2
0.35
2.22
Price-to-Peter-Lynch-Fair-Value 0.90
ICLR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
93% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. ICLR: 0.90 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ICLR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.08 Max: 3.26
Current: 0.9
0.2
3.26
Price-to-Graham-Number 4.10
ICLR's Price-to-Graham-Number is ranked lower than
54% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. ICLR: 4.10 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ICLR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.42  Med: 1.69 Max: 5.83
Current: 4.1
0.42
5.83
Earnings Yield (Greenblatt) % 5.48
ICLR's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. ICLR: 5.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICLR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.1  Med: 6.5 Max: 12.3
Current: 5.48
2.1
12.3
Forward Rate of Return (Yacktman) % 43.37
ICLR's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. ICLR: 43.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ICLR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 9.2 Max: 50.1
Current: 43.37
-15
50.1

More Statistics

Revenue (TTM) (Mil) $1,718.31
EPS (TTM) $ 4.93
Beta0.55
Short Percentage of Float2.36%
52-Week Range $73.76 - 117.53
Shares Outstanding (Mil)54.04 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,756 1,847 1,960
EPS ($) 5.29 5.83 6.46
EPS without NRI ($) 5.29 5.83 6.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.66%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}